M
Michael R. Green
Researcher at University of Texas MD Anderson Cancer Center
Publications - 597
Citations - 65007
Michael R. Green is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: RNA splicing & RNA. The author has an hindex of 126, co-authored 537 publications receiving 57447 citations. Previous affiliations of Michael R. Green include Eppley Institute for Research in Cancer and Allied Diseases & United States University.
Papers
More filters
Journal ArticleDOI
De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.
Alex K. Bryant,Kamya Sankar,Lili Zhao,Garth W. Strohbehn,David Elliott,Drew Moghanaki,Michael J. Kelley,Nithya Ramnath,Michael R. Green +8 more
TL;DR: In this paper , the effect of varying durations of adjuvant durvalumab treatment (up to 6, 9, and 12 months) on progression-free survival (PFS) and overall survival (OS) was compared with a marginal structural model and time-dependent Cox modelling.
Journal ArticleDOI
Transfer and Fixation of Denatured RNA in Agarose Gels to Membranes by Capillary Transfer.
Michael R. Green,Joseph Sambrook +1 more
TL;DR: This protocol presents the steps involved in the transfer of RNA from an agarose gel to a membranous support, facilitated by the upward flow of buffer, followed by various methods for fixation of the RNA to the membrane in preparation for hybridization.
Journal ArticleDOI
Characterization of a DNA polymerase activity in cultured human melanoma cells that copies poly(2'-O-methylcytidylate).
TL;DR: While utilizing poly(2’-O-methylcytidylate) oligodeoxyguanylate ((Cm),*(dG)lz-18) to assay for DNA polymerase activity during fractionation of total cell extracts of cultured human, malignant cells, a new DNA polymerases activity was identified in the human melanoma cell line A-375.
Journal ArticleDOI
Harnessing lymphoma epigenetics to improve therapies.
Haopeng Yang,Michael R. Green +1 more
TL;DR: Recently published studies centered on follicular lymphoma and diffuse large B-cell lymphoma are discussed within the context of prior knowledge, and how these insights have informed potential avenues for rational therapeutic interventions are highlighted.
Journal ArticleDOI
Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.
Alex K. Bryant,Kamya Sankar,Garth W. Strohbehn,Lili Zhao,Victoria Daniel,David Elliott,Nithya Ramnath,Michael R. Green +7 more
TL;DR: In this article , the authors determined pretreatment tumor programmed death ligand 1 (PD-L1) expression for 312 patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation and adjuvant durvalumab.